

Arsenic and cancer

ROBERT JACKSON,* MD, FRCP[C]; JACK W. GRAINGE,† MD

Summary: Palmar and plantar keratoses developed in seven patients many years after ingestion of trivalent inorganic arsenic. Six had basal cell carcinoma (superficial multicentric type in five), carcinoma "in situ" or squamous cell carcinoma of the skin. Two had systemic carcinoma — one, bilateral breast adenocarcinoma and one, carcinoma of the colon. From these observations and from the findings of a review of the literature, there seems no question that long-term arsenic ingestion can cause palmar and plantar keratoses and skin cancer, particularly basal cell carcinoma of the superficial multicentric type, usually on the torso. It is suspected but not proved to cause other cancers.

Although over the last 50 years general exposure to arsenic has greatly decreased, particularly that from insecticides, this element is still found occasionally in drinking water (naturally or as a smelter byproduct), in certain foods and in cigarette smoke.

Résumé: Arsenic et cancer

Chez sept malades nous avons observé des kératoses palmaires et plantaires plusieurs années après ingestion d'arsenic inorganique trivalent. Six avaient un carcinome de la cellule basale (de la forme multicentrique superficielle chez cinq), un carcinome "in situ" ou un carcinome cutané à cellules squameuses. Deux malades souffraient de carcinome général — un d'adénocarcinome mammaire bilatéral et l'autre d'un carcinome du côlon. De ces observations et des résultats d'une revue de la littérature, on peut conclure sans conteste que l'ingestion chronique d'arsenic cause des kératoses palmaires et plantaires et des carcinomes cutanés, principalement de la cellule basale de la forme multicentrique superficielle, siégeant d'habitude sur le torse. On soupçonne l'arsenic, sans en avoir de preuve formelle, de provoquer d'autres formes de cancer.

Bien que, depuis 50 ans, le contact fréquent avec l'arsenic ait diminué

considérablement, notamment en ce qui concerne les insecticides, cet élément se trouve encore parfois dans l'eau de boisson (à l'état naturel ou sous forme d'un produit de fusion), dans certains aliments et dans la fumée de cigarette.

For at least 2500 years arsenic has been used in medicine; Hippocrates, Aristotle, Dioscorides and Pliny the Elder are said to have used it. Over the past 150 years it has been an important drug: with it the physician was able to treat, with some success, dermatitis herpetiformis, asthma, syphilis, epilepsy, psoriasis, trypanosomiasis and amebiasis. These conditions, with the exception of trypanosomiasis and amebiasis, are now treated with modern, safer therapeutic agents.¹ Arsenic was also included in many medical "tonics".

The purpose of this paper is to demonstrate the correlation between long-term ingestion of inorganic trivalent arsenic (Fowler's solution; 1% potassium meta-arsenate, $KAsO_2$) and the development of malignant disease, particularly carcinoma of the skin (basal cell, "in situ" and squamous cell carcinoma), but also systemic carcinoma. We have reviewed the literature and collected results of a study of seven new cases.

Published evidence

Sir Jonathan Hutchinson, in 1887² and 1888,³ first clearly related the development of keratoses and skin cancer to long-term ingestion of arsenic as Fowler's solution. The second of his four patients² was Dr. James H. Whittemore, a 41-year-old resident physician at the Massachusetts General Hospital. From age 20 he had had psoriasis and had treated himself with large amounts of arsenic for long periods. "Corns" developed on his palms and soles at age 34. At age 40 his hands were amputated because of fungating growths. He died 18 months later with metastases in the axillary glands, lungs, kidneys, adrenals and ribs.

Clinical evidence that long-term ingestion of arsenic predisposes to skin and visceral cancer is also found in studies of populations whose drinking water has been contaminated with arsenic. For over 100 years the inhabitants of Reichenstein in Silesia drank arsenic-contaminated water. Gold ores containing arsenic were smelted in this

area, and arsenic from the fumes and slag contaminated the brooks from which drinking water was drawn. In one of these brooks arsenic was found in a concentration of 1.22 mg/dl (12.2 ppm*). In many of these people "Reichenstein's disease" developed, with gastrointestinal symptoms, mouth ulcers, perforation of the nasal septum, paresthesias and, especially, melanosis and keratoses of fingers and hands, and skin tumours in a high incidence. Over half of the people in the area died from visceral cancer.⁵ After 1928, when a new water supply was provided, the disease virtually disappeared.⁶

In the province of Cordoba in Argentina, where the well water has a high concentration of inorganic arsenic (0.28 to 0.45 mg/dl = 2.8 to 4.5 ppm), Ayerza's disease often develops after a person has drunk the polluted water for 5 or 6 years.⁷ Keratoses and keratoderma appear on the palms and soles, and skin cancers, mainly on the trunk and limbs. Liver and kidney ailments, often fatal, develop.

Lest one think that exposure to arsenic does not occur today, we have outlined in Table I four examples from the last 15 years in North America.

A selected review of the world literature on skin and internal cancer caused by ingestion of inorganic arsenic is outlined in Table II. Although the data are selected, they do show that of 916 individuals exposed to trivalent arsenic a skin cancer developed in 642 (70.1%) and an internal cancer in 58 (6.3%).

Present study

Methods

Seven cases were selected for study from the files of the Ontario Cancer Foundation and from our private files. Supplemental material was obtained from the charts of the Ottawa Civic Hospital and from personal interviews with the patients. The criteria used for selection were known long-term ingestion of inorganic arsenic (Fowler's solution) and signs of chronic arsenic intoxication, specifically keratoses of the palms and soles (Fig. 1). The duration of exposure was calculated from the time when arsenic therapy was begun.

*ppm = parts per million \approx mg/l. Recommended Canadian standards for drinking water are: acceptable, 0.01 ppm; maximum permissible, 0.05 ppm; and emergency, 0.3 ppm.⁴

*Dermatologist, Ottawa Civic Hospital; consultant dermatologist, Ontario Cancer Treatment and Research Foundation, Ottawa clinic

†Former resident in dermatology, Ottawa Civic Hospital

Reprint requests to: Dr. R. Jackson, Suite 508, 1081 Carling Ave., Ottawa, Ont. K1Y 4G2

Findings (Table III)

All seven patients in the study, three women and four men, were 60 years or older. Two patients had died at the time of the review. Onset of arsenic treatment varied from childhood to

young adulthood. In the four cases in which duration of treatment could be reliably determined the period varied from 17 to 25 years. In the other three cases, records allowed us to conclude confidently that therapy was of long duration (more than 5 years).

Palmar and plantar keratoses occurred in all the patients a minimum of 15 years and a median of 24 years after onset of arsenic therapy. Other keratoses occurred in two of the seven patients, on either the torso or the face.

Classically, the keratoses occur especially on the palms and soles but may be found anywhere on the skin. The most characteristic form is punctate keratoses of the palms and soles, with numerous small, horny, corn-like elevations, usually 2 to 5 mm in diameter. They occur frequently as epidermal pegs that can be picked out of their keratotic beds. They are frequently on the thenar and lateral borders of the hand, at the roots or on the side surfaces of the fingers, and sometimes also on the back of the phalangeal joints. On the soles the sites of predilection are the heels and the anterior portion of the soles. The corns may be confluent, forming wart-like excrescences, but, unlike true warts, they do not have a papillary structure and do not push apart the skin lines. Sometimes only the palms or the soles are affected. Rarely there is a more diffuse keratosis of the palms and soles, giving the skin a leathery appearance (diffuse keratoderma). The punctate, horny thickenings may be on an erythematous base, or a horny patch may be surrounded by an erythematous halo. Rarely the punctate keratoses are combined with the keratoderma. The keratoses of palms and soles are usually symmetrically distributed. Fissures may occur on the keratoses.

Table I—Examples of exposure to arsenic during last 15 years

Year and reference no.	Location	Source	Arsenic concentration (ppm*)	Disease and comments
1961 ⁸	Moira River basin, Madoc, Ont.	Smelting plant	Moira River 1971, 0.22 1972, 0.08 1973, 0.15 Moira Lake 1970, 0.09 1971-72, 0.05 1973, 0.04	None known.
1969 ⁹	Yellowknife, Northwest Territories	Gold mine smelter	Town water supply 1951-69 15% acceptable 70% below maximum permissible 15% above maximum permissible	Among 369 resident males, one basal cell carcinoma (type not stated). No mention of keratoses of palms or soles. High prevalence of chronic, nonspecific respiratory disease, neurologic abnormalities and electrocardiographic changes.
1973 ¹⁰	Perham, Minnesota	Well water	21 and 11.8 ppm	13 affected: mainly gastrointestinal complaints, acute and subacute intoxication.
1974 ¹¹	Montréal	Kelp preparation	16 to 58 µg/g of product (16 to 58 ppm)	None.

*ppm = parts per million.

Table II—Selected review of reports of cancer due to ingestion of inorganic arsenic

Year and reference no.	Total no. of patients	Source of arsenic	No. with cancer		Comments
			Skin	Internal	
1947 ⁶	143	Medicine	143	13	116 had keratoses of palms and soles. Definitive review up to 1947.
1953 ¹²	18*	Mainly Fowler's solution	18	6	Internal cancers: esophagus, 1; bladder, 2; colon, 1; tonsil, 1; lung, 1. Some had more than one type of cancer.
1957 ¹⁴	27	Moselle vintner's "house drink" (0.2 to 8.9 mg/dl of As ₂ O ₃ , or 2 to 89 ppm)	5	15	Internal cancers: bronchial, 12; malignant mesenchymal tumours of liver, 3. Postmortem studies in all 27.
1958 ¹⁵	16	Pesticides used by vineyard workers	7	11	Internal cancers: bronchial, 9; bile duct, 1; malignant lymph node, 1.
1958 ¹⁶	2	Medicine(1) Potato spray (1)	1	2	Internal cancers: hemangioendothelioma of liver, 1; carcinoma of head of pancreas, 1.
1963 ¹⁷	10	Medicine	10	None listed	
1964 ¹⁸	1	Medicine	1	1	Larynx and tongue cancers.
1965 ¹⁹	262	Medicine	21	None listed	40% had keratoses of palms and soles and 8% had skin cancers, both related to dose of arsenic.
1967 ²⁰	7	Pesticides used by vineyard workers	7	None listed	All had keratoses of palms and soles.
1968 ²¹	428	Well water (0.25 to 0.85 ppm)	428	9	Internal cancers: nasal fossa, 1; larynx, 1; bladder, 1; hepatomas, 4; "mediastinal" tumour, 1; rectal tumour, 1.
1968 ²²	1	Medicine	0	1	Hemangioendothelial sarcoma of liver.
1969 ²³	1	Medicine	1	0	
Total	916		642	58	

*A total of 27 patients, but 9 were previously reported¹³ and are included in the total of reference 6.




FIG. 1—Plantar keratoses (patient 5, present series).

The differential diagnosis of the punctate keratoses may include keratotic verrucae, multiple keratotic corns, keratotic psoriasis and other unusual types of keratosis punctata.

Basal cell carcinoma occurred in six of the seven patients a minimum of 15 years and a median of 43 years after onset of arsenic therapy. The superficial multicentric type of basal cell carcinoma occurred in all but patient 1. The lesions usually appeared on the torso but also occurred on the head and extremities. In five of the six patients the lesions were multiple; one patient had more than 50 tumours.

Carcinoma in situ developed in four of the seven patients a minimum of 39 years and a median of 44.5 years after onset of arsenic therapy. Lesions occurred on the chest, face, hand and leg. No patient had more than two lesions. Three patients had squamous cell carcinoma after a long period — 47, 50 and 51 years (median, 50 years). The sites of occurrence were the torso and the thigh. The number of lesions was recorded as few in one patient and only one in the other two patients.

Carcinoma other than of the skin occurred in two patients. In one an adenocarcinoma of the right breast developed 28 years after the onset of ingestion of arsenic and an adenocarcinoma of the left breast 11 years later.

In the second patient a carcinoma of the colon developed 63 years after onset of arsenic therapy.

One of the patients died from a basal cell carcinoma of the face that eroded through the skull and caused death from local extension. The other patient died from a myocardial infarction.

Discussion

Frost²⁴ did not believe arsenic is a carcinogen. While undoubtedly all who ingest arsenic in either drinking water or wine do not develop skin cancer it is obvious that some do. Yeh, How and Lin²¹ estimated that, among 40 421 inhabitants of 37 villages in Taiwan whose drinking water had a relatively high concentration of arsenic, 18.5% had skin manifestations of chronic arsenism (hyperpigmentation, keratoses or skin cancer).

Graham, Mazzanti and Helwig's²⁵ proposition that Bowen's disease in areas not exposed to sunlight is caused by arsenic ingestion has not been repeatedly shown to be true. Also, their patients did not regularly have palmar and plantar keratoses and superficial multicentric basal cell carcinomas on the torso — hallmarks of long-term ingestion of trivalent inorganic arsenic.

It is not easy to generalize on the type and location of cancers other than

of the skin reported in patients who have been exposed to trivalent inorganic arsenic, but basically they are found in the respiratory tract (tongue, tonsil, nasal fossa, larynx, lung) and gastrointestinal tract (esophagus, colon) as well as the liver and pancreas. Bladder cancer has occasionally been reported.

There are many ways in which a person can be exposed to arsenic. It can be ingested in drinking water, food or medicine, inhaled as a component of dust in the air or absorbed through the skin by contact with arsenical dusts or solutions. Because small amounts of arsenic are present in the environment (Table IV) everyone is exposed. Arsenic has been reported in large amounts in cigarettes (42 mg per cigarette²⁶) and presumably is in cigarette smoke.

Table IV—Common concentrations of arsenic in the environment²⁶

Source	Concentration (ppm)
Ground water	0 — 55
Surface water	0 — 80
Sea water	0.001 — 0.08
Fish food	3 — 170
Plants	0.023 — 0.25
Soil	0.03 — 0.25
Wine	0.008 — 0.85
Urban air	< 0.000077 — 0.00049*

* < 0.01-0.63 µg/m³

Table III—Summary of cases of seven patients with signs of chronic arsenic intoxication and history of long-term ingestion of inorganic trivalent arsenic

Patient no.	Age (yr)	Sex	Treatment		Palmar and plantar keratoses	Development of cancer; no. of years after onset of arsenic therapy							Cause of death	
			Age at onset (yr)	Duration (yr)		Onset	Basal cell carcinoma Type and no.	Carcinoma "in situ" Onset No.	Squamous cell carcinoma Onset No.	Carcinoma other than of skin	Other diseases			
1	60+	F	Childhood	Unknown	15	15	Multiple superficial multicentric, one deeply invasive	—	None	50	Few	—	—	Basal cell carcinoma, local invasion, age 60
2	75+	M	Approx. 20	Unknown	Unknown	41	Few superficial multicentric	44	2	—	None	—	Arteriosclerotic heart disease, hypertension, hyperthyroidism	Myocardial infarction, age 75
3	60	F	20	20	22	19	50+ superficial multicentric	39	1	—	None	—	—	Alive
4	63	F	Approx. 7	Approx. 25	28	45	Multiple superficial multicentric	45	1	47	1	Right breast, 28; Left breast, 39	—	Alive
5	71	M	7	24	24	53	Multiple superficial multicentric	48	1	—	None	Colon, 63	Acute cholecystitis	Alive
6	63	M	25	17	25	—	—	—	None	—	None	0	Myocardial infarction	Alive
7	87	M	Young man	Unknown	Unknown	50	Multiple superficial multicentric	—	None	51	1	0	Arteriosclerotic heart disease	Alive

Lasix[®]

for the long term

Composition: Each tablet contains 40 mg or 20 mg furosemide. Each 2 ml ampoule contains 20 mg furosemide; each 4 ml ampoule contains 40 mg. **Indications — Oral:** Mild to moderate hypertension or with other hypotensives in severe cases. Edema associated with congestive heart failure, cirrhosis of the liver, renal disease including the nephrotic syndrome, as well as other edematous states. **Parenteral:** Acute pulmonary, cardiac, hepatic or renal edema. **Contraindications:** Complete renal shutdown. Discontinue if increasing azotemia and oliguria occur during treatment of progressive renal disease. In hepatic coma and electrolyte depletion, do not institute therapy until the basic condition is improved or corrected. Until further experience has been accumulated, do not administer parenterally to children. **Warnings:** Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effects of tubocurarine. Exercise caution in administering curare or its derivatives during Lasix therapy. Discontinue 1 week prior to elective surgery. Cases of reversible deafness and tinnitus have been reported when Lasix Parenteral was given at doses exceeding several times the usual therapeutic dose of 20 to 40 mg. Transient deafness is more likely to occur in patients with severe impairment of renal function and in patients also receiving drugs known to be ototoxic. **Precautions:** Inject Lasix Parenteral slowly [1 to 2 minutes] when i.v. route is used. Sodium intake should be not less than 3 g/day. Potassium supplements should be given when high doses are used over prolonged periods. Caution with potassium levels is desirable when on digitalis glycosides, potassium-depleting steroids, or in impending hepatic coma. Potassium supplementation, diminution in dose, or discontinuation of Lasix may be required. Aldosterone antagonists should be added when treating severe cirrhosis with ascites. Reproduction studies in animals have produced no evidence of drug-induced fetal abnormalities. Lasix has had only limited use in pregnancy and should be used only when deemed essential. Check urine and blood glucose as decreased glucose tolerance has been observed. Check serum calcium levels as rare cases of tetany have been reported. Patients receiving high doses of salicylates with Lasix may experience salicylate toxicity at lower doses. **Adverse reactions:** As with any effective diuretic, electrolyte depletion may occur especially with high doses and restricted salt intake. Electrolyte depletion may manifest itself by weakness, dizziness, lethargy, leg cramps, anorexia, vomiting and/or mental confusion. Check serum electrolytes, especially potassium at higher dose levels. In edematous hypertensives reduce the dosage of other antihypertensives since Lasix potentiates their effect. Asymptomatic hyperuricemia can occur and gout may rarely be precipitated. Reversible elevations of BUN may be seen especially in renal insufficiency. Dermatitis, pruritus, paresthesia, blurring of vision, postural hypotension, nausea, vomiting, or diarrhea may occur. Anemia, leukopenia, and thrombocytopenia [with purpura] and rare cases of agranulocytosis have occurred. Weakness, fatigue, dizziness, muscle cramps, thirst, increased perspiration, bladder spasm and symptoms of urinary frequency may occur. **Overdose:** Symptoms: Dehydration and electrolyte depletion. Treatment: Discontinue drug and institute water and electrolyte replacement. **Dosage and administration — Oral:** Hypertension: Usual dosage is 40 to 80 mg daily. Individualize therapy and adjust dosage of concomitant hypotensive therapy. **Edema:** Usual initial dosage is 40 to 80 mg. Adjust according to response. If diuresis has not occurred after 6 hours, increase dosage by increments of 40 mg as frequently as every 6 hours if necessary. The effective dose can then be repeated 1 to 3 times daily. A maximum daily dose of 200 mg should not be exceeded. Maintenance dosage must be adjusted individually. An intermittent dosage schedule of 2 to 4 consecutive days each week may be utilized. With doses exceeding 120 mg/day, clinical and laboratory observations are advisable. **Parenteral:** Usual dosage is 20 to 40 mg given as a single dose, injected i.m. or i.v. The i.v. injection should be given slowly [1 to 2 minutes]. Ordinarily, a prompt diuresis ensues. If diuresis is not satisfactory, succeeding doses may be increased by increments of 20 mg 2 hours after the previous dose, until the required diuresis is obtained. The maximum recommended daily dosage is 100 mg. Acute pulmonary edema: Administer 40 mg immediately by slow i.v. injection. May be followed by another 40 mg 1 to 1½ hours later. **Pediatric use:** Institute Lasix orally under close observation in the hospital. Single oral dose is 0.5 to 1 mg/kg. The daily oral dose should not exceed 2 mg/kg in divided doses. In newborns and pretermatures, the daily oral dose should not exceed 1 mg/kg. Particular caution with potassium levels is desirable. Do not administer to jaundiced newborns or infants suffering from diseases with the potential of causing hyperbilirubinemia and possibly kernicterus. **Supply:** Yellow, round, scored 40 mg tablets [Code DL] in bottles of 50 and 500. White round 20 mg tablets [Code DLF] in bottles of 30. Amber ampoules of 2 ml in boxes of 5 and 50; 4 ml in boxes of 50. Complete information on request.

 **HOECHST**

Hoechst Pharmaceuticals, Division of Canadian Hoechst Ltd., Montreal

1229/7065/E

Reg Hoechst TM

All forms of arsenic are not equally carcinogenic. Almost all reports indicate that the trivalent inorganic form is the real culprit. The pentavalent inorganic form only rarely is reported as causing cancer; it is assumed that there is some breakdown from the pentavalent to the trivalent form. The organic arsenical compounds, particularly the antisyphilitics such as arsenphenamine (salvarsan) and nearsphenamine (neosalvarsan) and oxophenarsine hydrochloride (Mapharsen), are not carcinogenic because the arsenic ion is not readily available as a cellular toxin.²⁶

One problem in establishing the carcinogenic activity of arsenic is that no animal models exist. Apparently arsenic does not affect animals in the same way as it does humans. Another problem is the difficulty in determining exact amounts of arsenic ingested in patients with evidence of chronic arsenic intoxication. Neubauer⁶ and Fierz¹⁹ tried to do this, and Fierz showed that the incidence of palmar and plantar keratoses and skin carcinoma increased with larger doses of the arsenical. There are no comparable figures for carcinomas of sites other than skin supposedly induced by arsenic.

The arsenic does not remain in the tissues for the total time required for the keratoses or skin cancers to develop; it certainly stays there for some years, but not the 10 to 15 or 20 years that often pass before the manifestation of lengthy arsenic exposure becomes obvious. Presumably some cellular change is induced by the arsenic and continues even in its absence. In our series the median time from commencing ingestion to onset of lesions was 24 years for palmar and plantar keratoses, 43 years for basal cell carcinoma, 44.5 years for carcinoma in situ and 50 years for squamous cell carcinoma. By the time neoplasms have developed, the concentrations of arsenic in the skin, hair and nails may have returned to normal and it is impossible to prevent more lesions developing by removing residual traces of arsenic by treatment with dimercaprol (BAL).²⁷

We thank J.W. Grainge, Sr., MSP(Eng.) of Edmonton for his assistance.

References

- GOODMAN LS, GILMAN A: *The Pharmacological Basis of Therapeutics*, fourth ed. London and Toronto, Macmillan, 1970, pp 958-65
- HUTCHINSON J: Arsenic cancer. *Br Med J* 2: 1280, 1887
- Idem: On some examples of arsenic keratoses of the skin and of arsenic cancer. *Trans Pathol Soc Lond* 39: 352, 1888
- Canadian Drinking Water Standards and Objectives 1968*. Ottawa, Department of National Health and Welfare, 1969

- GEYER L: Über die chronischen Hautveränderungen beim Arsenicismus und Betrachtungen über die Massenerkrankungen in Reichenstein in Schlesien. *Arch Dermatol Syphilol Wein* 43: 221, 1898
- NEUBAUER O: Arsenical cancer: a review. *Br J Cancer* 1: 192, 1947
- TELLO EE: Les epitheliomes d'origine arsenicale. *Rev Fac Cien Med Cordoba* 20: 197, 1962
- The Globe and Mail*, Toronto, Oct 20, 1973, p 10
- DE VILLIERS AJ, BAKER PM: *An Investigation of the Health Status of Inhabitants of Yellowknife, Northwest Territories*. Occupational health division, environmental health directorate, Department of National Health and Welfare, Ottawa
- FEINGLASS EJ: Arsenic intoxication from well water in the United States. *N Engl J Med* 288: 828, 1973
- WALKIW O, DOUGLAS DE: Health food supplements prepared from kelp — a source of elevated urinary arsenic (C). *Can Med Assoc J* 111: 1301, 1974
- SOMMERS SC, MCMANUS RG: Multiple arsenical cancers of skin and internal organs. *Cancer* 6: 347, 1953
- FRANSEEN CC, TAYLOR GW: Arsenical keratoses and carcinomas. *Am J Cancer* 22: 287, 1934
- ROTH F: The sequelae of chronic arsenic poisoning in Moselle vintners. *Germ Med Mon* 2: 172, 1957
- BRAUN W: Carcinoma of the skin and the internal organs caused by arsenic. *Ger Med Mon* 23: 321, 1958
- ROSSET M: Arsenical keratoses associated with carcinomas of the internal organs. *Can Med Assoc J* 78: 416, 1958
- SANDERSON KV: Arsenic and skin cancer. *Trans St Johns Hosp Dermatol Soc* 49: 115, 1963
- MINKOWITZ S: Multiple carcinomata following ingestion of medicinal arsenic. *Ann Intern Med* 61: 296, 1964
- FIERZ U: Follow up investigation of side effects of therapy with inorganic arsenicals in skin diseases. *Dermatologica* 131: 41, 1965
- THIERS H, COLOMB D, MOULIN G, et al: Le cancer cutané arsenical des viticulteurs du Beaujolais. *Ann Dermatol Syphilol (Paris)* 94: 133, 1967
- YEH S, HOW SW, LIN CS: Arsenical cancer of skin. *Cancer* 21: 312, 1968
- REGELSON W, KIM U, OSPINA J, et al: Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. *Ibid*, p 514
- NOVEY HS, MARTEL SH: Asthma, arsenic and cancer. *J Allergy* 44: 315, 1969
- FROST DV: Arsenic and cancer. *Ibid*, p 320
- GRAHAM JH, MAZZANTI GR, HELWIG EB: Chemistry of Bowen's disease: relationship to arsenic. *J Invest Dermatol* 37: 317, 1961
- GRAINGE JW: *Water Pollution, Yellowknife Bay, Northwest Territories*. Edmonton, Public health engineering division, Department of National Health and Welfare, 1963
- Arsenic and cancer (E). *Br Med J* 2: 191, 1968

Postgraduate Courses

SYMPOSIUM — LES ULCÈRES GASTRODUODÉNAUX. Université Laval. Les 21-22 novembre 1975. Renseignements: Dr Robert Gourdeau, Faculté de médecine, Université Laval, Québec, Qué. K1K 7P4

CREATIVE SEXUALITY. Hotel Toronto. Nov. 26 to 28, 1975. Seminar with Drs. Noam and Beryl Cherrick. Information: Creative Sexuality, Ste. 400, 73 Richmond St., Toronto, Ont. M5H 2A1